Post-traumatic Stress Disorder in Middle Age and Beyond
Objective
To review the clinical manifestations and treatment of post-traumatic stress disorder (PTSD) in adults and older people.
Data Sources
Articles indexed in PubMed, Embase, psychology databases, and the Cochrane library over the past 10 years using the key words “post-traumatic stress disorder,” “stress disorders,” and “post-traumatic stress disorder and treatment.”
Study Selection and Data Extraction
Sixty-seven publications were reviewed and criteria supporting the primary objective were used to identify useful resources.
Data Synthesis
The literature included practice guidelines; review articles; original research articles; and product prescribing information for the clinical manifestations, diagnosis, and treatment of PTSD.
Conclusion
Psychotherapy is the first-line therapy for PTSD. Pharmacologic therapy is recommended, as second-line therapy, for adults living with PTSD who do not have access to psychotherapy or refuse psychotherapy. Pharmacologic therapy may also be considered in cases of partial, or no, response to psychotherapy. Current guidelines recommend prescribing one of 3 selective serotonin-reuptake inhibitors, either fluoxetine, paroxetine, or sertraline, or prescribing the serotonin norepinephrine reuptake inhibitor venlafaxine, for adult patients who do not have access to psychotherapy or prefer not to use psychotherapy. Unfortunately, these recommended medications have additional cautions for use in older people so may not be appropriate for many older people living with PTSD. Therapy for older people should be tailored to patient-specific symptoms, with careful consideration of the potential benefits and risks of the therapy and coexisting medical conditions of each patient.
To review the clinical manifestations and treatment of post-traumatic stress disorder (PTSD) in adults and older people.
Data Sources
Articles indexed in PubMed, Embase, psychology databases, and the Cochrane library over the past 10 years using the key words “post-traumatic stress disorder,” “stress disorders,” and “post-traumatic stress disorder and treatment.”
Study Selection and Data Extraction
Sixty-seven publications were reviewed and criteria supporting the primary objective were used to identify useful resources.
Data Synthesis
The literature included practice guidelines; review articles; original research articles; and product prescribing information for the clinical manifestations, diagnosis, and treatment of PTSD.
Conclusion
Psychotherapy is the first-line therapy for PTSD. Pharmacologic therapy is recommended, as second-line therapy, for adults living with PTSD who do not have access to psychotherapy or refuse psychotherapy. Pharmacologic therapy may also be considered in cases of partial, or no, response to psychotherapy. Current guidelines recommend prescribing one of 3 selective serotonin-reuptake inhibitors, either fluoxetine, paroxetine, or sertraline, or prescribing the serotonin norepinephrine reuptake inhibitor venlafaxine, for adult patients who do not have access to psychotherapy or prefer not to use psychotherapy. Unfortunately, these recommended medications have additional cautions for use in older people so may not be appropriate for many older people living with PTSD. Therapy for older people should be tailored to patient-specific symptoms, with careful consideration of the potential benefits and risks of the therapy and coexisting medical conditions of each patient.
Keywords: Antidepressants; Geriatrics; Pharmacotherapy; Post-traumatic stress disorder; Psychotherapy; Trauma
Document Type: Case Report
Affiliations: 1Mercer University College of Pharmacy, Mercer Health Sciences Center, Atlanta, Georgia.
Publication date: April 1, 2021
- The Senior Care Pharmacist® is the official peer-reviewed journal of the American Society of Consultant Pharmacists. It is dedicated exclusively to the medication needs of the elderly in all settings, including adult day care, ambulatory care, assisted living, community, hospice, and nursing facilities. This award-winning journal is a member benefit of ASCP. Individuals who are not members and wish to receive The Senior Care Pharmacist® will want to consider joining ASCP.
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- ">
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content